{"organizations": [], "uuid": "d266c844b13d907eb80e8764b213f003d8ac44c5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-auris-medical-announces-further-re/brief-auris-medical-announces-further-results-from-healos-phase-3-trial-idUSFWN1OZ0PY", "country": "US", "domain_rank": 408, "title": "BRIEF-Auris Medical Announces Further Results From Healos Phase 3 Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T19:43:00.000+02:00", "replies_count": 0, "uuid": "d266c844b13d907eb80e8764b213f003d8ac44c5"}, "author": "", "url": "https://www.reuters.com/article/brief-auris-medical-announces-further-re/brief-auris-medical-announces-further-results-from-healos-phase-3-trial-idUSFWN1OZ0PY", "ord_in_thread": 0, "title": "BRIEF-Auris Medical Announces Further Results From Healos Phase 3 Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "sec", "sentiment": "none"}, {"name": "healos phase 3 trial reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 5:44 PM / Updated 7 minutes ago BRIEF-Auris Medical Announces Further Results From Healos Phase 3 Trial Reuters Staff 1 Min Read \nJan 4 (Reuters) - Auris Medical Holding Ag: \n* AURIS MEDICAL HOLDING AG SAYS ANNOUNCED FURTHER CLINICAL RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL, PROVIDES UPDATE ON AM-111 DEVELOPMENT PROGRAM \n* AURIS MEDICAL HOLDING AG SAYS AM-111 TREATED PATIENTS HAD A LOWER INCIDENCE OF NO HEARING IMPROVEMENT- SEC FILING \n* AURIS MEDICAL HOLDING SAYS POST-HOC ANALYSES OF TOP-LINE DATA REVEALED CLINICALLY AND STATISTICALLY SIGNIFICANT HEARING IMPROVEMENT WITH AM-111 \n* AURIS MEDICAL HOLDING SAYS PLANS TO DISCUSS ACCUMULATED SAFETY AND EFFICACY DATA AND REGULATORY PATHWAY WITH FDA AND EMA IN Q2 OF 2018. Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T19:43:00.000+02:00", "crawled": "2018-01-04T20:06:20.007+02:00", "highlightTitle": ""}